Inconclusive Findings in Non-Vitamin K Antagonist Oral Anticoagulants Study

To the Editor We read with interest the nationwide population-based cohort study with meta-analysis by Tsai et al. The study findings showed that patients who received non-vitamin K antagonist oral anticoagulants (NOACs) before a stroke, compared with those receiving warfarin and those without oral anticoagulant treatment (non-OAC), did not experience a higher risk of intracranial hemorrhage (ICH), major bleeding events, or mortality when treated with intravenous alteplase for acute ischemic stroke. In comparison with the active comparator (warfarin group), the odds ratios (ORs) were 0.88 (95% CI, 0.32-2.40) for ICH, 0.82 (95% CI, 0.34-1.97) for major bleeding, and 0.31 (95% CI, 0.08-1.18) for in-hospital mortality.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research